PCSK9 and coronary artery disorder: PCSK9 binds hepatic low-density lipoprotein receptor (LDLR) and promotes its degradation, which results in increased plasma low-density lipoprotein cholesterol (LDL-C) concentrations and higher risk of coronary artery disease (CAD) [2].